IMMUNE NETWORK

  • 제24권1호
  • /
  • Pages.4.1-4.19
  • /
  • 2024
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지
DOI QR코드

DOI QR Code

TNF in Human Tuberculosis: A Double-Edged Sword

  • Jae-Min Yuk (Infection Control Convergence Research Center, Chungnam National University College of Medicine) ;
  • Jin Kyung Kim (Department of Microbiology, Keimyung University School of Medicine) ;
  • In Soo Kim (Department of Medical Science, Chungnam National University College of Medicine) ;
  • Eun-Kyeong Jo (Infection Control Convergence Research Center, Chungnam National University College of Medicine)
  • 투고 : 2023.08.09
  • 심사 : 2024.01.10
  • 발행 : 2024.02.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

TNF, a pleiotropic proinflammatory cytokine, is important for protective immunity and immunopathology during Mycobacterium tuberculosis (Mtb) infection, which causes tuberculosis (TB) in humans. TNF is produced primarily by phagocytes in the lungs during the early stages of Mtb infection and performs diverse physiological and pathological functions by binding to its receptors in a context-dependent manner. TNF is essential for granuloma formation, chronic infection prevention, and macrophage recruitment to and activation at the site of infection. In animal models, TNF, in cooperation with chemokines, contributes to the initiation, maintenance, and clearance of mycobacteria in granulomas. Although anti-TNF therapy is effective against immune diseases such as rheumatoid arthritis, it carries the risk of reactivating TB. Furthermore, TNF-associated inflammation contributes to cachexia in patients with TB. This review focuses on the multifaceted role of TNF in the pathogenesis and prevention of TB and underscores the importance of investigating the functions of TNF and its receptors in the establishment of protective immunity against and in the pathology of TB. Such investigations will facilitate the development of therapeutic strategies that target TNF signaling, which makes beneficial and detrimental contributions to the pathogenesis of TB.

키워드

과제정보

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Korea government (MSIT) (NRF-2017R1A5A2015385, NRF-2022R1C1C1004346, and RS-2023-00255021).

참고문헌

  1. Russell DG. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunol Rev 2011;240:252-268.
  2. Alsayed SSR, Gunosewoyo H. Tuberculosis: pathogenesis, current treatment regimens and new drug targets. Int J Mol Sci 2023;24:5202.
  3. Ruiz A, Palacios Y, Garcia I, Chavez-Galan L. Transmembrane TNF and its receptors TNFR1 and TNFR2 in mycobacterial infections. Int J Mol Sci 2021;22:5461.
  4. Dostert C, Grusdat M, Letellier E, Brenner D. The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiol Rev 2019;99:115-160.
  5. Coppola M, Villar-Hernandez R, van Meijgaarden KE, Latorre I, Muriel Moreno B, Garcia-Garcia E, Franken KL, Prat C, Stojanovic Z, De Souza Galvao ML, et al. Cell-mediated immune responses to in vivo-expressed and stage-specific Mycobacterium tuberculosis antigens in latent and active tuberculosis across different age groups. Front Immunol 2020;11:103.
  6. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, Ulevitch R, Cerami A. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316:552-554.
  7. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666-3670.
  8. O'Malley WE, Achinstein B, Shear MJ. Action of bacterial polysaccharide on tumors. Iii. repeated response of sarcoma 37, in tolerant mice, to serratia marcescens endotoxin. Cancer Res 1963;23:890-895.
  9. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372-377.
  10. Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 1985;260:2345-2354.
  11. Yang S, Wang J, Brand DD, Zheng SG. Role of TNF-TNF receptor 2 signal in regulatory T cells and its therapeutic implications. Front Immunol 2018;9:784.
  12. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002;27:19-26.
  13. Chedotal H, Narayanan D, Povlsen K, Gotfredsen CH, Brambilla R, Gajhede M, Bach A, Clausen MH. Small-molecule modulators of tumor necrosis factor signaling. Drug Discov Today 2023;28:103575.
  14. Jacobs M, Brown N, Allie N, Chetty K, Ryffel B. Tumor necrosis factor receptor 2 plays a minor role for mycobacterial immunity. Pathobiology 2000;68:68-75.
  15. Shundo Y, On R, Matsumoto T, Ouchi H, Fujita M. TNFR1 mediated apoptosis is protective against Mycobacterium avium in mice. Microorganisms 2023;11:778.
  16. Roca FJ, Ramakrishnan L. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 2013;153:521-534.
  17. Souza RF, Caetano MAF, Magalhaes HIR, Castelucci P. Study of tumor necrosis factor receptor in the inflammatory bowel disease. World J Gastroenterol 2023;29:2733-2746.
  18. Naude PJ, den Boer JA, Luiten PG, Eisel UL. Tumor necrosis factor receptor cross-talk. FEBS J 2011;278:888-898.
  19. Wong KW. The role of ESX-1 in Mycobacterium tuberculosis pathogenesis. Microbiol Spectr 2017;5.
  20. Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: host defense vs pathogen evasion. Cell Mol Immunol 2017;14:963-975.
  21. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-820.
  22. Ray JC, Flynn JL, Kirschner DE. Synergy between individual TNF-dependent functions determines granuloma performance for controlling Mycobacterium tuberculosis infection. J Immunol 2009;182:3706-3717.
  23. Chai Q, Lu Z, Liu CH. Host defense mechanisms against Mycobacterium tuberculosis. Cell Mol Life Sci 2020;77:1859-1878.
  24. Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat Rev Immunol 2017;17:691-702.
  25. Kiran D, Podell BK, Chambers M, Basaraba RJ. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. Semin Immunopathol 2016;38:167-183.
  26. Tsai MC, Chakravarty S, Zhu G, Xu J, Tanaka K, Koch C, Tufariello J, Flynn J, Chan J. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol 2006;8:218-232.
  27. Patel K, Jhamb SS, Singh PP. Models of latent tuberculosis: their salient features, limitations, and development. J Lab Physicians 2011;3:75-79.
  28. Tonko S, Baty F, Brutsche MH, Schoch OD. Length of hospital stay for TB varies with comorbidity and hospital location. Int J Tuberc Lung Dis 2020;24:948-955.
  29. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 2012;16:153-166.
  30. Paval DR, Patton R, McDonald J, Skipworth RJE, Gallagher IJ, Laird BJ; Caledonian Cachexia Collaborative. A systematic review examining the relationship between cytokines and cachexia in incurable cancer. J Cachexia Sarcopenia Muscle 2022;13:824-838.
  31. Balsano R, Kruize Z, Lunardi M, Comandatore A, Barone M, Cavazzoni A, Re Cecconi AD, Morelli L, Wilmink H, Tiseo M, et al. Transforming growth factor-beta signaling in cancer-induced cachexia: from molecular pathways to the clinics. Cells 2022;11:2671.
  32. Mupere E, Malone L, Zalwango S, Okwera A, Nsereko M, Tisch DJ, Parraga IM, Stein CM, Mugerwa R, Boom WH, et al. Wasting among Uganda men with pulmonary tuberculosis is associated with linear regain in lean tissue mass during and after treatment in contrast to women with wasting who regain fat tissue mass: prospective cohort study. BMC Infect Dis 2014;14:24.
  33. Linge I, Kondratieva E, Apt A. Prolonged B-lymphocyte-mediated immune and inflammatory responses to tuberculosis infection in the lungs of TB-resistant mice. Int J Mol Sci 2023;24:1140.
  34. Lopetuso LR, Cuomo C, Mignini I, Gasbarrini A, Papa A. Focus on anti-tumour necrosis factor (TNF)-α-related autoimmune diseases. Int J Mol Sci 2023;24:8187.
  35. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008;8:601-611.
  36. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.
  37. Harris J, Hope JC, Keane J. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J Infect Dis 2008;198:1842-1850.
  38. Mezouar S, Diarra I, Roudier J, Desnues B, Mege JL. Tumor necrosis factor-alpha antagonist interferes with the formation of granulomatous multinucleated giant cells: new insights into Mycobacterium tuberculosis infection. Front Immunol 2019;10:1947.
  39. Bo H, Moure UAE, Yang Y, Pan J, Li L, Wang M, Ke X, Cui H. Mycobacterium tuberculosis-macrophage interaction: molecular updates. Front Cell Infect Microbiol 2023;13:1062963.
  40. Pattanaik KP, Sengupta S, Jit BP, Kotak R, Sonawane A. Host-mycobacteria conflict: immune responses of the host vs. the mycobacteria TLR2 and TLR4 ligands and concomitant host-directed therapy. Microbiol Res 2022;264:127153.
  41. Gopalakrishnan A, Salgame P. Toll-like receptor 2 in host defense against Mycobacterium tuberculosis: to be or not to be-that is the question. Curr Opin Immunol 2016;42:76-82.
  42. Ruiz A, Guzman-Beltran S, Carreto-Binaghi LE, Gonzalez Y, Juarez E. DNA from virulent M. tuberculosis induces TNF-α production and autophagy in M1 polarized macrophages. Microb Pathog 2019;132:166-177.
  43. Nguyen H, Gazy N, Venketaraman V. A role of intracellular toll-like receptors (3, 7, and 9) in response to Mycobacterium tuberculosis and co-infection with HIV. Int J Mol Sci 2020;21:6148.
  44. Kwon KW, Kang TG, Lee A, Jin SM, Lim YT, Shin SJ, Ha SJ. Protective efficacy and immunogenicity of Rv0351/Rv3628 subunit vaccine formulated in different adjuvants against Mycobacterium tuberculosis infection. Immune Netw 2023;23:e16.
  45. Wang LX, Zhang SX, Wu HJ, Rong XL, Guo J. M2b macrophage polarization and its roles in diseases. J Leukoc Biol 2019;106:345-358.
  46. Ahmad F, Rani A, Alam A, Zarin S, Pandey S, Singh H, Hasnain SE, Ehtesham NZ. Macrophage: a cell with many faces and functions in tuberculosis. Front Immunol 2022;13:747799.
  47. Rutschmann O, Toniolo C, McKinney JD. Preexisting heterogeneity of inducible nitric oxide synthase expression drives differential growth of Mycobacterium tuberculosis in macrophages. MBio 2022;13:e0225122.
  48. Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium tuberculosis. Nat Rev Microbiol 2022;20:750-766.
  49. Cambier CJ, Takaki KK, Larson RP, Hernandez RE, Tobin DM, Urdahl KB, Cosma CL, Ramakrishnan L. Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. Nature 2014;505:218-222.
  50. Mohareer K, Banerjee S. Mycobacterial infection alters host mitochondrial activity. Int Rev Cell Mol Biol 2023;377:87-119.
  51. Mendonca LE, Pernet E, Khan N, Sanz J, Kaufmann E, Downey J, Grant A, Orlova M, Schurr E, Krawczyk C, et al. Human alveolar macrophage metabolism is compromised during Mycobacterium tuberculosis infection. Front Immunol 2023;13:1044592.
  52. Tukiman MH, Norazmi MN. Immunometabolism of immune cells in mucosal environment drives effector responses against Mycobacterium tuberculosis. Int J Mol Sci 2022;23:8531.
  53. Palma C, La Rocca C, Gigantino V, Aquino G, Piccaro G, Di Silvestre D, Brambilla F, Rossi R, Bonacina F, Lepore MT, et al. Caloric restriction promotes immunometabolic reprogramming leading to protection from tuberculosis. Cell Metab 2021;33:300-318.e12.
  54. Marrocco A, Ortiz LA. Role of metabolic reprogramming in pro-inflammatory cytokine secretion from LPS or silica-activated macrophages. Front Immunol 2022;13:936167.
  55. Mahla RS, Kumar A, Tutill HJ, Krishnaji ST, Sathyamoorthy B, Noursadeghi M, Breuer J, Pandey AK, Kumar H. NIX-mediated mitophagy regulate metabolic reprogramming in phagocytic cells during mycobacterial infection. Tuberculosis (Edinb) 2021;126:102046.
  56. O Maoldomhnaigh C, Cox DJ, Phelan JJ, Mitermite M, Murphy DM, Leisching G, Thong L, O'Leary SM, Gogan KM, McQuaid K, et al. Lactate alters metabolism in human macrophages and improves their ability to kill Mycobacterium tuberculosis. Front Immunol 2021;12:663695.
  57. van der Meer JW, Joosten LA, Riksen N, Netea MG. Trained immunity: a smart way to enhance innate immune defence. Mol Immunol 2015;68:40-44.
  58. Murphy DM, Mills KHG, Basdeo SA. The effects of trained innate immunity on T cell responses; clinical implications and knowledge gaps for future research. Front Immunol 2021;12:706583.
  59. Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LA, van der Meer JW, Mhlanga MM, Mulder WJ, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol 2020;20:375-388.
  60. Rawat BS, Kumar D, Soni V, Rosenn EH. Therapeutic potentials of immunometabolomic modulations induced by tuberculosis vaccination. Vaccines (Basel) 2022;10:2127.
  61. Arts RJ, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R, Kleinnijenhuis J, Lachmandas E, Goncalves LG, Belinha A, et al. Immunometabolic pathways in BCG-induced trained immunity. Cell Reports 2016;17:2562-2571.
  62. Koeken VA, Qi C, Mourits VP, de Bree LC, Moorlag SJ, Sonawane V, Lemmers H, Dijkstra H, Joosten LA, van Laarhoven A, et al. Plasma metabolome predicts trained immunity responses after antituberculosis BCG vaccination. PLoS Biol 2022;20:e3001765.
  63. Strazar M, Mourits VP, Koeken VA, de Bree LC, Moorlag SJ, Joosten LA, van Crevel R, Vlamakis H, Netea MG, Xavier RJ. The influence of the gut microbiome on BCG-induced trained immunity. Genome Biol 2021;22:275.
  64. Bickett TE, McLean J, Creissen E, Izzo L, Hagan C, Izzo AJ, Silva Angulo F, Izzo AA. Characterizing the BCG induced macrophage and neutrophil mechanisms for defense against Mycobacterium tuberculosis. Front Immunol 2020;11:1202.
  65. Espert L, Beaumelle B, Vergne I. Autophagy in Mycobacterium tuberculosis and HIV infections. Front Cell Infect Microbiol 2015;5:49.
  66. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000;290:1717-1721.
  67. Xu Y, Shen J, Ran Z. Emerging views of mitophagy in immunity and autoimmune diseases. Autophagy 2020;16:3-17.
  68. Kleinnijenhuis J, Oosting M, Plantinga TS, van der Meer JW, Joosten LA, Crevel RV, Netea MG. Autophagy modulates the Mycobacterium tuberculosis-induced cytokine response. Immunology 2011;134:341-348.
  69. Anandaiah A, Sinha S, Bole M, Sharma SK, Kumar N, Luthra K, Li X, Zhou X, Nelson B, Han X, et al. Vitamin D rescues impaired Mycobacterium tuberculosis-mediated tumor necrosis factor release in macrophages of HIV-seropositive individuals through an enhanced Toll-like receptor signaling pathway in vitro. Infect Immun 2013;81:2-10.
  70. Bongiovanni B, Mata-Espinosa D, D'Attilio L, Leon-Contreras JC, Marquez-Velasco R, Bottasso O, Hernandez-Pando R, Bay ML. Effect of cortisol and/or DHEA on THP1-derived macrophages infected with Mycobacterium tuberculosis. Tuberculosis (Edinb) 2015;95:562-569.
  71. Sharma N, Shariq M, Quadir N, Singh J, Sheikh JA, Hasnain SE, Ehtesham NZ. Mycobacterium tuberculosis protein PE6 (Rv0335c), a novel TLR4 agonist, evokes an inflammatory response and modulates the cell death pathways in macrophages to enhance intracellular survival. Front Immunol 2021;12:696491.
  72. Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K, Vokes M, Bray MA, Carpenter AE, Moore CB, Siddiqi N, et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog 2014;10:e1003946.
  73. Lee YJ, Kim JK, Jung CH, Kim YJ, Jung EJ, Lee SH, Choi HR, Son YS, Shim SM, Jeon SM, et al. Chemical modulation of SQSTM1/p62-mediated xenophagy that targets a broad range of pathogenic bacteria. Autophagy 2022;18:2926-2945.
  74. Racanelli AC, Kikkers SA, Choi AM, Cloonan SM. Autophagy and inflammation in chronic respiratory disease. Autophagy 2018;14:221-232.
  75. Nisa A, Kipper FC, Panigrahy D, Tiwari S, Kupz A, Subbian S. Different modalities of host cell death and their impact on Mycobacterium tuberculosis infection. Am J Physiol Cell Physiol 2022;323:C1444-C1474.
  76. Lam A, Prabhu R, Gross CM, Riesenberg LA, Singh V, Aggarwal S. Role of apoptosis and autophagy in tuberculosis. Am J Physiol Lung Cell Mol Physiol 2017;313:L218-L229.
  77. Mohareer K, Asalla S, Banerjee S. Cell death at the cross roads of host-pathogen interaction in Mycobacterium tuberculosis infection. Tuberculosis (Edinb) 2018;113:99-121.
  78. Jayaraman P, Sada-Ovalle I, Nishimura T, Anderson AC, Kuchroo VK, Remold HG, Behar SM. IL-1β promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation. J Immunol 2013;190:4196-4204.
  79. Balcewicz-Sablinska MK, Keane J, Kornfeld H, Remold HG. Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J Immunol 1998;161:2636-2641.
  80. Satti I, Wittenberg RE, Li S, Harris SA, Tanner R, Cizmeci D, Jacobs A, Williams N, Mulenga H, Fletcher HA, et al. Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants. Nat Commun 2022;13:6594.
  81. Saghazadeh A, Rezaei N. Central inflammatory cytokines in tuberculous meningitis: a systematic review and meta-analysis. J Interferon Cytokine Res 2022;42:95-107.
  82. Muefong CN, Owolabi O, Donkor S, Charalambous S, Mendy J, Sey IC, Bakuli A, Rachow A, Geldmacher C, Sutherland JS. Major neutrophil-derived soluble mediators associate with baseline lung pathology and post-treatment recovery in tuberculosis patients. Front Immunol 2021;12:740933.
  83. Sampath P, Rajamanickam A, Thiruvengadam K, Natarajan AP, Hissar S, Dhanapal M, Thangavelu B, Jayabal L, Ramesh PM, Ranganathan UD, et al. Cytokine upsurge among drug-resistant tuberculosis endorse the signatures of hyper inflammation and disease severity. Sci Rep 2023;13:785.
  84. Tellez-Navarrete NA, Ramon-Luing LA, Munoz-Torrico M, Preciado-Garcia M, Medina-Quero K, Hernandez-Pando R, Chavez-Galan L. Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time. Mol Med 2021;27:76.
  85. Mily A, Sarker P, Taznin I, Hossain D, Haq MA, Kamal SMM, Raqib R. Slow radiological improvement and persistent low-grade inflammation after chemotherapy in tuberculosis patients with type 2 diabetes. BMC Infect Dis 2020;20:933.
  86. Tezera LB, Bielecka MK, Ogongo P, Walker NF, Ellis M, Garay-Baquero DJ, Thomas K, Reichmann MT, Johnston DA, Wilkinson KA, et al. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. eLife 2020;9:e52668.
  87. Wang Y, Sun Q, Zhang Y, Li X, Liang Q, Guo R, Zhang L, Han X, Wang J, Shao L, et al. Systemic immune dysregulation in severe tuberculosis patients revealed by a single-cell transcriptome atlas. J Infect 2023;86:421-438.
  88. Remijsen Q, Goossens V, Grootjans S, Van den Haute C, Vanlangenakker N, Dondelinger Y, Roelandt R, Bruggeman I, Goncalves A, Bertrand MJ, et al. Depletion of RIPK3 or MLKL blocks TNF-driven necroptosis and switches towards a delayed RIPK1 kinase-dependent apoptosis. Cell Death Dis 2014;5:e1004.
  89. Xu G, Wang J, Gao GF, Liu CH. Insights into battles between Mycobacterium tuberculosis and macrophages. Protein Cell 2014;5:728-736.
  90. Cui Y, Tang Y, Shao M, Zang X, Jiang Y, Cui Z, Dang G, Liu S. Mycobacterium tuberculosis protease Rv3090 is associated with late cell apoptosis and participates in organ injuries and mycobacterial dissemination in mice. Microb Pathog 2022;173:105880.
  91. Roca FJ, Whitworth LJ, Redmond S, Jones AA, Ramakrishnan L. TNF induces pathogenic programmed macrophage necrosis in tuberculosis through a mitochondrial-lysosomal-endoplasmic reticulum circuit. Cell 2019;178:1344-1361.e11.
  92. Roca FJ, Whitworth LJ, Prag HA, Murphy MP, Ramakrishnan L. Tumor necrosis factor induces pathogenic mitochondrial ROS in tuberculosis through reverse electron transport. Science 2022;376:eabh2841.
  93. Kim TS, Jin YB, Kim YS, Kim S, Kim JK, Lee HM, Suh HW, Choe JH, Kim YJ, Koo BS, et al. SIRT3 promotes antimycobacterial defenses by coordinating mitochondrial and autophagic functions. Autophagy 2019;15:1356-1375.